PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
23786757-4	2013	The aim of this study was to investigate Annexin A1 expression in pre-treatment biopsies from a cohort of OSCC patients treated with surgery and post-operative radiotherapy or docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy followed by surgery and post-operative radiotherapy.	TPF	217-220	annexin A1	Homo sapiens	41-51
24277397-2	2013	METHODS: Patients with colon cancer were divided into TP group and TPF-FOS group.	TPF	67-70	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	71-74
24277397-7	2013	Higher proportion of patients defecated formed stool during the observation in TPF-FOS group(76.7% vs. 27.3%, P<0.01).	TPF	79-82	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	83-86
24277397-8	2013	Less abdominal bloating was found from the fourth to the seventh postoperative day in TPF-FOS group (5.8% vs. 15.2%, P<0.05).	TPF	86-89	Fos proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	90-93
23786757-14	2013	Patients with moderate/poorly differentiated OSCC and low Annexin A1 expression can benefit from the addition of TPF induction chemotherapy to surgery and post-operative radiotherapy.	TPF	113-116	annexin A1	Homo sapiens	58-68
23786757-15	2013	Annexin A1 expression can potentially be used as a predictive biomarker to select OSCC patients with moderate/poorly differentiated tumor who may benefit from TPF induction chemotherapy.	TPF	159-162	annexin A1	Homo sapiens	0-10
21229356-10	2011	CONCLUSION: CCRT with TPF or PFML regimen for advanced oropharyngeal SCC is tolerable and effective, especially in patients with resectable disease.	TPF	22-25	serpin family B member 3	Homo sapiens	69-72
23515614-6	2013	However, patients with nodal stage cN2 whose tumors had high cyclin D1 expression treated with TPF had significantly greater OS (P = 0.025) and DMFS (P = 0.025) when compared with high cyclin D1 cN2 patients treated with surgery upfront.	TPF	95-98	carnosine dipeptidase 2	Homo sapiens	35-38
23515614-6	2013	However, patients with nodal stage cN2 whose tumors had high cyclin D1 expression treated with TPF had significantly greater OS (P = 0.025) and DMFS (P = 0.025) when compared with high cyclin D1 cN2 patients treated with surgery upfront.	TPF	95-98	cyclin D1	Homo sapiens	61-70
23515614-8	2013	This study indicates that cN2 OSCC patients with high cyclin D1 expression can benefit from the addition of TPF induction chemotherapy to standard treatment.	TPF	108-111	carnosine dipeptidase 2	Homo sapiens	26-29
23515614-8	2013	This study indicates that cN2 OSCC patients with high cyclin D1 expression can benefit from the addition of TPF induction chemotherapy to standard treatment.	TPF	108-111	cyclin D1	Homo sapiens	54-63
14981927-11	2003	Therefore we can show for the first time that the effect of TPF, which is now used as a novel Phase II protocol for induction chemotherapy in head and neck cancer, could be highly significantly enhanced through the addition of anti-EGFR antibodies.	TPF	60-63	epidermal growth factor receptor	Mus musculus	232-236
18788641-1	2008	OBJECTIVE: This clinical study was designed to evaluate the efficacy and toxicity of the combined regimen of docetaxel, 5-Fu and DDP (TPF) in the treatment of advanced or relapsed nasopharyngeal carcinoma (NPC).	TPF	134-137	translocase of inner mitochondrial membrane 8A	Homo sapiens	129-132
20864569-5	2011	Promising results were shown in phase II trials in which the anti-epidermal growth factor receptor monoclonal antibody cetuximab was added to induction therapy with TPF, docetaxel/cisplatin, or paclitaxel/carboplatin, and in some of these studies, to subsequent CRT.	TPF	165-168	epidermal growth factor receptor	Homo sapiens	66-98
17096160-3	2007	In this study, we report the results of hyperfractionation (Hfx) RTx with concurrent docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy (CTx) in patients with locally advanced SCCHN and compare Hfx and Cfx RTx with concurrent TPF CTx.	TPF	126-129	cytochrome P450 family 27 subfamily A member 1	Homo sapiens	145-148
16415064-4	2006	The in vivo activation state of ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco) and the level of ribulose-1,5-bisphosphate (RuBP) in TpF-11, TpS-10 and TpS-11 were significantly higher than those in the wild-type plants.	TPF	143-146	alpha,alpha-trehalose-phosphate synthase [UDP-forming] 1-like	Nicotiana tabacum	151-154
16415064-4	2006	The in vivo activation state of ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco) and the level of ribulose-1,5-bisphosphate (RuBP) in TpF-11, TpS-10 and TpS-11 were significantly higher than those in the wild-type plants.	TPF	143-146	alpha,alpha-trehalose-phosphate synthase [UDP-forming] 1-like	Nicotiana tabacum	162-165
34157171-2	2021	This study aims to explore the relationship between the Annexin A1 expression and the clinical response to cisplatin, docetaxel, and 5-fluorouracil (TPF) as induction chemotherapy in patients with oral squamous cell carcinoma (OSCC).	TPF	149-152	annexin A1	Homo sapiens	56-66
9021722-10	1997	We conclude that high TPF (greater than 40 as measured by staining with MiB-1) strongly correlates with malignancy and, therefore, may be useful in the diagnosis of carcinomas.	TPF	22-25	MIB E3 ubiquitin protein ligase 1	Homo sapiens	72-77
1747449-5	1991	In addition, TPF enhanced the acetylcholinesterase (Ach-E) activity of megakaryocytes induced by rh-Epo.	TPF	13-16	acetylcholinesterase	Mus musculus	30-50
1747449-5	1991	In addition, TPF enhanced the acetylcholinesterase (Ach-E) activity of megakaryocytes induced by rh-Epo.	TPF	13-16	acetylcholinesterase	Mus musculus	52-57
1747449-5	1991	In addition, TPF enhanced the acetylcholinesterase (Ach-E) activity of megakaryocytes induced by rh-Epo.	TPF	13-16	erythropoietin	Mus musculus	100-103
34826159-1	2022	The aim of this study was to: 1) explore the potential mechanism of cancer cell sensitivity to cisplatin, docetaxel, and 5-fluorouracil (TPF) in oral squamous cell carcinoma (OSCC) patients overexpressing growth differentiation factor 15 (GDF15); and 2) identify potential alternative agents for patients who might not benefit from inductive TPF chemotherapy.	TPF	137-140	growth differentiation factor 15	Homo sapiens	205-237
34826159-1	2022	The aim of this study was to: 1) explore the potential mechanism of cancer cell sensitivity to cisplatin, docetaxel, and 5-fluorouracil (TPF) in oral squamous cell carcinoma (OSCC) patients overexpressing growth differentiation factor 15 (GDF15); and 2) identify potential alternative agents for patients who might not benefit from inductive TPF chemotherapy.	TPF	137-140	growth differentiation factor 15	Homo sapiens	239-244
34826159-1	2022	The aim of this study was to: 1) explore the potential mechanism of cancer cell sensitivity to cisplatin, docetaxel, and 5-fluorouracil (TPF) in oral squamous cell carcinoma (OSCC) patients overexpressing growth differentiation factor 15 (GDF15); and 2) identify potential alternative agents for patients who might not benefit from inductive TPF chemotherapy.	TPF	342-345	growth differentiation factor 15	Homo sapiens	205-237
34826159-1	2022	The aim of this study was to: 1) explore the potential mechanism of cancer cell sensitivity to cisplatin, docetaxel, and 5-fluorouracil (TPF) in oral squamous cell carcinoma (OSCC) patients overexpressing growth differentiation factor 15 (GDF15); and 2) identify potential alternative agents for patients who might not benefit from inductive TPF chemotherapy.	TPF	342-345	growth differentiation factor 15	Homo sapiens	239-244
9158680-10	1997	High TPF (> 80), as measured by staining with MiB-1, and positive p53 strongly correlate with malignant behavior and therefore may be useful in distinguishing benign from malignant adrenal lesions.	TPF	5-8	MIB E3 ubiquitin protein ligase 1	Homo sapiens	49-54
34575229-1	2021	This study aims to evaluate the relationship between human ribophorin II (RPN2) and the effect of treatment using induction therapy with docetaxel, cisplatin, and fluorouracil (TPF) for p-16 negative locally advanced head and neck squamous cell carcinoma (HNSCC).	TPF	177-180	ribophorin II	Homo sapiens	59-72
34575229-1	2021	This study aims to evaluate the relationship between human ribophorin II (RPN2) and the effect of treatment using induction therapy with docetaxel, cisplatin, and fluorouracil (TPF) for p-16 negative locally advanced head and neck squamous cell carcinoma (HNSCC).	TPF	177-180	ribophorin II	Homo sapiens	74-78
34575229-4	2021	Our study showed that RPN2 overexpression was significantly correlated with a poor response to induction chemotherapy with TPF.	TPF	123-126	ribophorin II	Homo sapiens	22-26
34157171-6	2021	RESULTS: We found that reduced expression of Annexin A1 conferred a prognostic benefit from induction chemotherapy based on the TPF drug combination in patients with moderately/poorly differentiated disease.	TPF	128-131	annexin A1	Homo sapiens	45-55
34157171-10	2021	CONCLUSION: Annexin A1 may be of prognostic value in patients with locally advanced OSCC who are managed with TPF chemotherapy, as low Annexin A1 promotes chemosensitivity to TPF chemotherapy in oral cancer cells via enhanced caspase-dependent apoptosis.	TPF	110-113	annexin A1	Homo sapiens	12-22
34157171-10	2021	CONCLUSION: Annexin A1 may be of prognostic value in patients with locally advanced OSCC who are managed with TPF chemotherapy, as low Annexin A1 promotes chemosensitivity to TPF chemotherapy in oral cancer cells via enhanced caspase-dependent apoptosis.	TPF	175-178	annexin A1	Homo sapiens	12-22
34157171-10	2021	CONCLUSION: Annexin A1 may be of prognostic value in patients with locally advanced OSCC who are managed with TPF chemotherapy, as low Annexin A1 promotes chemosensitivity to TPF chemotherapy in oral cancer cells via enhanced caspase-dependent apoptosis.	TPF	175-178	annexin A1	Homo sapiens	135-145
35196761-11	2022	Conclusion: GPR68 and CD8+T cells are expected to be biomarkers for evaluating the efficacy and prognosis of TPF-induced chemotherapy in patients with middle-advanced hypopharyngeal squamous cell carcinoma.	TPF	109-112	G protein-coupled receptor 68	Homo sapiens	12-17
35453553-0	2022	Serum Levels of Stromal Cell-Derived Factor-1alpha and Vascular Endothelial Growth Factor Predict Clinical Outcomes in Head and Neck Squamous Cell Carcinoma Patients Receiving TPF Induction Chemotherapy.	TPF	176-179	vascular endothelial growth factor A	Homo sapiens	55-89
35196761-11	2022	Conclusion: GPR68 and CD8+T cells are expected to be biomarkers for evaluating the efficacy and prognosis of TPF-induced chemotherapy in patients with middle-advanced hypopharyngeal squamous cell carcinoma.	TPF	109-112	CD8a molecule	Homo sapiens	22-25
32934722-2	2020	Based on our previous phase 3 trial on TPF (docetaxel, cisplatin and fluorouracil) induction chemotherapy in patients with oral squamous cell carcinoma (OSCC), in which short-term prognostic and predictive values of cyclin D1 expression were reported, the present study aimed to determine the long-term predictive value of cyclin D1 expression in the same patients with OSCC who were eligible to receive TPF induction chemotherapy.	TPF	39-42	cyclin D1	Homo sapiens	216-225
32934722-2	2020	Based on our previous phase 3 trial on TPF (docetaxel, cisplatin and fluorouracil) induction chemotherapy in patients with oral squamous cell carcinoma (OSCC), in which short-term prognostic and predictive values of cyclin D1 expression were reported, the present study aimed to determine the long-term predictive value of cyclin D1 expression in the same patients with OSCC who were eligible to receive TPF induction chemotherapy.	TPF	39-42	cyclin D1	Homo sapiens	323-332
32934722-7	2020	Furthermore, patients with stage clinical nodal stage 2 (cN2) OSCC in the high cyclin D1 expression group benefitted from TPF induction chemotherapy (OS, P=0.024; DMFS, P=0.024), whilst patients with cN2 OSCC in the low cyclin D1 expression group did not benefit from this chemotherapy.	TPF	122-125	cyclin D1	Homo sapiens	79-88
32538743-1	2020	This study aimed to explore the clinical value of miR-92b in advanced oral squamous cell carcinoma (OSCC) and to observe the relationship between miR-92b and TPF induced chemotherapy and prognosis.	TPF	158-161	microRNA 92b	Homo sapiens	146-153
32194755-0	2020	Changes of serum miR-223-3p in patients with oral cancer treated with TPF regimen and the prognosis.	TPF	70-73	microRNA 223	Homo sapiens	17-24
31994271-4	2020	We analyzed the predictive value of stathmin on TPF induction chemotherapy and its impact on OSCC cell chemosensitivity.	TPF	48-51	stathmin 1	Homo sapiens	36-44
31994271-7	2020	Stathmin overexpression promoted cellular proliferation and decreased OSCC cell sensitivity to TPF treatment.	TPF	95-98	stathmin 1	Homo sapiens	0-8
31054505-10	2019	TPF could also decrease the expression levels of some pro-inflammatory factors, high dose TPF treated mice were with the reduction of (202.29 +- 18.58) pg/ml (tumor necrosis factor alpha, TNF-alpha), (53.69 +- 7.83) pg/ml (interleukin (IL)-1beta, IL-1beta), (48.44 +- 3.77) pg/ml (IL-6I, L-6) to the model separately.	TPF	90-93	interleukin 1 alpha	Mus musculus	247-255
32074750-14	2020	Conclusion: CD44 and IL-6R may be potentially functional genes of TPF induction chemotherapy in hypopharyngeal squamous cell carcinoma.	TPF	66-69	CD44 molecule (Indian blood group)	Homo sapiens	12-16
32074750-14	2020	Conclusion: CD44 and IL-6R may be potentially functional genes of TPF induction chemotherapy in hypopharyngeal squamous cell carcinoma.	TPF	66-69	interleukin 6 receptor	Homo sapiens	21-26
32426701-1	2020	Objective: To investigate the expressions of MAPK10, c-Jun and Itga6 in laryngeal carcinoma and its influence on the sensitivity to docetaxel, cisplatin and 5-fluorouracil (TPF) chemotherapy.	TPF	173-176	mitogen-activated protein kinase 10	Homo sapiens	45-51
31054505-10	2019	TPF could also decrease the expression levels of some pro-inflammatory factors, high dose TPF treated mice were with the reduction of (202.29 +- 18.58) pg/ml (tumor necrosis factor alpha, TNF-alpha), (53.69 +- 7.83) pg/ml (interleukin (IL)-1beta, IL-1beta), (48.44 +- 3.77) pg/ml (IL-6I, L-6) to the model separately.	TPF	0-3	tumor necrosis factor	Mus musculus	159-186
31054505-10	2019	TPF could also decrease the expression levels of some pro-inflammatory factors, high dose TPF treated mice were with the reduction of (202.29 +- 18.58) pg/ml (tumor necrosis factor alpha, TNF-alpha), (53.69 +- 7.83) pg/ml (interleukin (IL)-1beta, IL-1beta), (48.44 +- 3.77) pg/ml (IL-6I, L-6) to the model separately.	TPF	0-3	tumor necrosis factor	Mus musculus	188-197
31489406-6	2019	After underexpression of ANXA1, cell growth rate increased, cell cycle accelerated, sensitivity to TPF chemotherapeutic drugs increased, and reverse EMT occurred in OSCC.	TPF	99-102	annexin A1	Homo sapiens	25-30
31054505-10	2019	TPF could also decrease the expression levels of some pro-inflammatory factors, high dose TPF treated mice were with the reduction of (202.29 +- 18.58) pg/ml (tumor necrosis factor alpha, TNF-alpha), (53.69 +- 7.83) pg/ml (interleukin (IL)-1beta, IL-1beta), (48.44 +- 3.77) pg/ml (IL-6I, L-6) to the model separately.	TPF	0-3	interleukin 1 beta	Mus musculus	222-245
31054505-10	2019	TPF could also decrease the expression levels of some pro-inflammatory factors, high dose TPF treated mice were with the reduction of (202.29 +- 18.58) pg/ml (tumor necrosis factor alpha, TNF-alpha), (53.69 +- 7.83) pg/ml (interleukin (IL)-1beta, IL-1beta), (48.44 +- 3.77) pg/ml (IL-6I, L-6) to the model separately.	TPF	0-3	interleukin 1 alpha	Mus musculus	247-255
31054505-10	2019	TPF could also decrease the expression levels of some pro-inflammatory factors, high dose TPF treated mice were with the reduction of (202.29 +- 18.58) pg/ml (tumor necrosis factor alpha, TNF-alpha), (53.69 +- 7.83) pg/ml (interleukin (IL)-1beta, IL-1beta), (48.44 +- 3.77) pg/ml (IL-6I, L-6) to the model separately.	TPF	90-93	tumor necrosis factor	Mus musculus	159-186
31054505-10	2019	TPF could also decrease the expression levels of some pro-inflammatory factors, high dose TPF treated mice were with the reduction of (202.29 +- 18.58) pg/ml (tumor necrosis factor alpha, TNF-alpha), (53.69 +- 7.83) pg/ml (interleukin (IL)-1beta, IL-1beta), (48.44 +- 3.77) pg/ml (IL-6I, L-6) to the model separately.	TPF	90-93	tumor necrosis factor	Mus musculus	188-197
31054505-10	2019	TPF could also decrease the expression levels of some pro-inflammatory factors, high dose TPF treated mice were with the reduction of (202.29 +- 18.58) pg/ml (tumor necrosis factor alpha, TNF-alpha), (53.69 +- 7.83) pg/ml (interleukin (IL)-1beta, IL-1beta), (48.44 +- 3.77) pg/ml (IL-6I, L-6) to the model separately.	TPF	90-93	interleukin 1 beta	Mus musculus	222-245
31489406-5	2019	RESULTS: After overexpression of ANXA1, cell growth rate decreased, cell cycle slowed down, sensitivity to TPF-induced drugs decreased, and EMT occurred in OSCC.	TPF	107-110	annexin A1	Homo sapiens	33-38
29344407-0	2018	TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma.	TPF	0-3	CD274 molecule	Homo sapiens	37-42
29948238-1	2018	BACKGROUND: The efficacy of primary prophylactic granulocyte colony-stimulating factor (G-CSF) in preventing febrile neutropenia (FN) in patients treated with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy remains controversial.	TPF	201-204	colony stimulating factor 3	Homo sapiens	49-86
29948238-1	2018	BACKGROUND: The efficacy of primary prophylactic granulocyte colony-stimulating factor (G-CSF) in preventing febrile neutropenia (FN) in patients treated with docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy remains controversial.	TPF	201-204	colony stimulating factor 3	Homo sapiens	88-93
29731919-8	2018	Furthermore, the cT3/4N0M0 patients with high GDF15 expression benefited significantly from TPF induction chemotherapy, including overall survival (HR=0.233; P=0.02), disease-free survival (HR=0.296; P=0.014), locoregional recurrence-free survival (HR=0.347; P=0.035) and distant metastasis-free survival (HR=0.212; P=0.013) rates.	TPF	92-95	growth differentiation factor 15	Homo sapiens	46-51
29731919-10	2018	Elevated GDF15 expression in cT3/4N0M0 patients predicts significant long-term benefit of survival from TPF induction chemotherapy.	TPF	104-107	growth differentiation factor 15	Homo sapiens	9-14
29721176-7	2018	Conclusions: On the basis of our results, we recommend primary prophylactic use of granulocyte colony-stimulating factor and/or antibiotics selectively for patients predicted to be at high risk for TPF chemotherapy-induced FN.	TPF	198-201	colony stimulating factor 3	Homo sapiens	83-120
29344407-2	2018	Whether induction docetaxel, platinum and fluorouracil (TPF) modifies PD-L1 expression or tumour immune infiltrates is unknown.	TPF	56-59	CD274 molecule	Homo sapiens	70-75
29344407-11	2018	Tumour-infiltrating CD8+ mean densities also significantly increased post-TPF (P=0.01).	TPF	74-77	CD8a molecule	Homo sapiens	20-23
29344407-13	2018	Conclusion: TPF induction chemotherapy in advanced HNSCC increases PD-L1 positivity on tumour-infiltrating ICs, as well as CD8+ lymphocytes density.	TPF	12-15	CD274 molecule	Homo sapiens	67-72
29344407-13	2018	Conclusion: TPF induction chemotherapy in advanced HNSCC increases PD-L1 positivity on tumour-infiltrating ICs, as well as CD8+ lymphocytes density.	TPF	12-15	CD8a molecule	Homo sapiens	123-126
28729771-7	2017	Moreover, in vitro cell culture experiments revealed the expression alternations of IL-6, MAPK14, JUN, CDK5 and CAMK2A exposed to TPF treatment by qRT-PCR, whilst providing an insight into the mechanism underlying TPF chemotherapeutic response in HSCC.	TPF	130-133	interleukin 6	Homo sapiens	84-88
28729771-7	2017	Moreover, in vitro cell culture experiments revealed the expression alternations of IL-6, MAPK14, JUN, CDK5 and CAMK2A exposed to TPF treatment by qRT-PCR, whilst providing an insight into the mechanism underlying TPF chemotherapeutic response in HSCC.	TPF	130-133	mitogen-activated protein kinase 14	Homo sapiens	90-96
28729771-7	2017	Moreover, in vitro cell culture experiments revealed the expression alternations of IL-6, MAPK14, JUN, CDK5 and CAMK2A exposed to TPF treatment by qRT-PCR, whilst providing an insight into the mechanism underlying TPF chemotherapeutic response in HSCC.	TPF	130-133	cyclin dependent kinase 5	Homo sapiens	103-107
28729771-7	2017	Moreover, in vitro cell culture experiments revealed the expression alternations of IL-6, MAPK14, JUN, CDK5 and CAMK2A exposed to TPF treatment by qRT-PCR, whilst providing an insight into the mechanism underlying TPF chemotherapeutic response in HSCC.	TPF	130-133	calcium/calmodulin dependent protein kinase II alpha	Homo sapiens	112-118
27486286-11	2016	NACT followed by CCRT demonstrated significantly superior DFS as compared to definitive CCRT, respectively, TPF (hazard ratio (HR) = 0.248, 95 % confidence interval (CI) 0.123-0.500; p < 0.001), PF (HR = 0.445, 95 % CI 0.266-0.722; p = 0.002).	TPF	108-111	solute carrier family 13 member 5	Homo sapiens	0-4
27050716-11	2016	CONCLUSION: In patients who had received adjuvant TPF for node-positive penile squamous cell carcinoma, p53 IHC expression seemed to be associated with a poorer outcome, and further study is warranted in larger data sets to confirm these findings.	TPF	50-53	tumor protein p53	Homo sapiens	104-107
25973606-5	2015	We discovered that a high protein level of LDHB in OSCC patients was associated with a poor response to TPF regimen chemotherapy as well as poor overall survival and disease-free survival.	TPF	104-107	lactate dehydrogenase B	Homo sapiens	43-47
26556875-6	2015	Combining blockade of p-STAT3 with cytotoxic drugs cisplatin, docetaxel, 5-fluorouracil (TPF) enhanced the antitumor effect in vitro and in vivo with decreased tumor sphere formation and SP cells.	TPF	89-92	signal transducer and activator of transcription 3	Mus musculus	22-29
25917382-1	2016	BACKGROUND: This study evaluated the significance of mammalian target of rapamycin (mTOR) activation on the prognosis of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF).	TPF	276-279	mechanistic target of rapamycin kinase	Homo sapiens	53-82
25917382-1	2016	BACKGROUND: This study evaluated the significance of mammalian target of rapamycin (mTOR) activation on the prognosis of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil (TPF).	TPF	276-279	mechanistic target of rapamycin kinase	Homo sapiens	84-88
25917382-4	2016	RESULTS: Phosphorylated-mTOR expression was independently significantly associated with response to TPF, progression-free survival (PFS), and overall survival (OS).	TPF	100-103	mechanistic target of rapamycin kinase	Homo sapiens	24-28
26872381-6	2016	Furthermore, elevated TFE3 expression was observed in HNSCC after cisplatin-based chemotherapy, and high TFE3 expression may indicate poor response to TPF inductive chemotherapy.	TPF	151-154	transcription factor binding to IGHM enhancer 3	Homo sapiens	105-109
25973606-9	2015	In conclusion, our study highlighted the critical role of LDHB in OSCC and proposed that LDHB could be used as a biomarker for the stratification of patients for TPF neoadjuvant chemotherapy and the determination of prognosis in OSCC patients.	TPF	162-165	lactate dehydrogenase B	Homo sapiens	89-93
25085076-1	2014	The aim of this study was to investigate the prognostic and predictive values of phospholipase C gamma 1 (PLCG1) expression in patients with locally advanced and resectable oral squamous cell carcinoma (OSCC), who were treated in a prospective, randomized, phase 3 trial evaluating standard treatment with surgery and postoperative radiation preceded or not by induction docetaxel, cisplatin, and 5-fluorouracil (TPF).	TPF	413-416	phospholipase C gamma 1	Homo sapiens	81-104
25085076-1	2014	The aim of this study was to investigate the prognostic and predictive values of phospholipase C gamma 1 (PLCG1) expression in patients with locally advanced and resectable oral squamous cell carcinoma (OSCC), who were treated in a prospective, randomized, phase 3 trial evaluating standard treatment with surgery and postoperative radiation preceded or not by induction docetaxel, cisplatin, and 5-fluorouracil (TPF).	TPF	413-416	phospholipase C gamma 1	Homo sapiens	106-111
25085076-4	2014	Patients with a low PLCG1 expression had a significantly better overall survival (P=0.022), and a trend towards better disease-free survival (P=0.087), loco-regional recurrence-free survival (P=0.058), distant metastasis-free survival (P=0.053), and a high response rate to TPF induction chemotherapy with regard to clinical response (P=0.052) and pathological response (P=0.061), compared to those with high PLCG1 expression.	TPF	274-277	phospholipase C gamma 1	Homo sapiens	20-25